Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: A randomized, blinded crossover trial

Arthritis Care and Research

Volumn 66, Issue 8, 2014, Pages 1246-1251

  Solomon, Daniel H ^a   Garg, Rajesh ^a   Lu, Bing ^a   Todd, Derrick J ^a   Mercer, Emileigh ^a   Norton, Tabatha ^a   Massarotti, Elena ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAS28; DIABETES MELLITUS; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HOMEOSTATIC MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SENSITIVITY INDEX; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID PARAMETERS; MALE; METABOLIC PARAMETERS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84905020121     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22285     Document Type: Article

References (15)

1. Lafyatis R, York M, Marshak-Rothstein A,. Antimalarial agents: closing the gate on toll-like receptors? Arthritis Rheum 2006; 54: 3068-70.
2. Fox RI, Kang HI,. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; Suppl 1: S9-12.
3. Basque J, Martel M, Leduc R, Cantin AM,. Lysosomotropic drugs inhibit maturation of transforming growth factor-β. Can J Physiol Pharmacol 2008; 86: 606-12.
4. Emami J, Gerstein HC, Pasutto FM, Jamali F,. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol 1999; 77: 118-23.
5. Shojania K, Koehler BE, Elliott T,. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999; 26: 195-6.
6. Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: a new job for an old drug? Ann Intern Med 1990; 112: 678-81.
7. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB,. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas: a randomized trial. Diabetes Res Clin Pract 2002; 55: 209-19.
8. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298: 187-93.
9. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S,. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-31.
10. Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH,. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals [letter]. Arthritis Res Ther 2012; 14: R135.
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
12. Matsuda M, DeFronzo RA,. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-70.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
14. Petri M, Lakatta C, Magder L, Goldman D,. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254-9.
15. Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J,. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997; 3: 3-8.